Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Ahmet Zehir, Ryma Benayed, Ronak Shah et al. · Nature Medicine · 2017 · 3.5K citations

Medicine, Genetics, Oncology +16

Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer

Jürgen Wolf, Takashi Seto, Ji‐Youn Han et al. · New England Journal of Medicine · 2020 · 997 citations · Full text

Medicine, Oncology, Pharmacology +15

The landscape of kinase fusions in cancer

Nicolas Stransky, Ethan Cerami, Stefanie S. Schalm et al. · Nature Communications · 2014 · 969 citations · Full text

Medicine, Cancer Biology, Oncology +17

Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations

Paul K. Paik, Enriqueta Felip, Rémi Veillon et al. · New England Journal of Medicine · 2020 · 854 citations · Full text

Medicine, Oncology, Pharmacology +15

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

Garrett M. Frampton, Siraj M. Ali, Mark R. Rosenzweig et al. · Cancer Discovery · 2015 · 796 citations · Full text

Medicine, Molecular Genetics, Oncology +16